IMUX: Immunic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for IMUX
Across the 27 sessions after earlier IMUX headlines, the stock closed higher 18 times and lower 8 times, with a median move of 4.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IMUX | SPY |
|---|---|---|---|
| Aug 11, 2026 | Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Updateand 1 other headline that session | +9.8% | -0.3% |
| Jul 9, 2026 | Immunic to Participate in Investor Conferences in July | +0.1% | +0.8% |
| Jun 10, 2026 | Immunic to Participate in Investor, Industry and Scientific Conferences in June | -4.5% | -1.6% |
| May 28, 2026 | Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis | +6.9% | +0.6% |
| May 27, 2026 | Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer | +7.9% | -0.0% |
| May 22, 2026 | Wolfe Research initiated coverage on Immunic | +6.1% | +0.4% |
Quantisnow market dataNASDAQ
IMUX
Immunic Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for IMUX
Full IMUX profile on Quantisnow Follow IMUX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time